{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:16:35Z","timestamp":1774890995490,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,11,24]],"date-time":"2011-11-24T00:00:00Z","timestamp":1322092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11523-011-0200-y","type":"journal-article","created":{"date-parts":[[2011,11,26]],"date-time":"2011-11-26T01:30:46Z","timestamp":1322271046000},"page":"227-233","source":"Crossref","is-referenced-by-count":41,"title":["Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents"],"prefix":"10.1007","volume":"6","author":[{"given":"Andreia","family":"Costa","sequence":"first","affiliation":[]},{"given":"Sabine","family":"Tejpar","sequence":"additional","affiliation":[]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,11,24]]},"reference":[{"key":"200_CR1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CCO.0b013e32833edbdf","volume":"22","author":"I Vivancoa","year":"2010","unstructured":"Vivancoa I, Mellinghoff K (2010) Epidermal growth factor receptor inhibitors in oncology. Curr Op Oncol 22:573\u2013578","journal-title":"Curr Op Oncol"},{"key":"200_CR2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.critrevonc.2009.03.012","volume":"73","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Bahleda R, Khayat D et al (2010) Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 73:213\u2013219","journal-title":"Crit Rev Oncol Hematol"},{"key":"200_CR3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2009.02.001","volume":"35","author":"J Capdevila","year":"2009","unstructured":"Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echari M, Tabernero J (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 35:354\u2013363","journal-title":"Cancer Treat Rev"},{"key":"200_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1152\/physrev.2001.81.1.51","volume":"81","author":"LJ Dai","year":"2001","unstructured":"Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA (2001) Magnesium transport in the renal distal convoluted tubule. Physiol Rev 81:51\u201384","journal-title":"Physiol Rev"},{"key":"200_CR5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2741\/Romani","volume":"5","author":"AM Romani","year":"2000","unstructured":"Romani AM, Scarpa A (2000) Regulation of cellular magnesium. Front Bioscien 5:720\u2013734","journal-title":"Front Bioscien"},{"key":"200_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1677\/joe.0.1130117","volume":"113","author":"O Ferment","year":"1987","unstructured":"Ferment O, Garnier PE, Touitou Y (1987) Comparison of the feedback effect of magnesium and calcium on parathyroid hormone secretion in man. J Endocrinol 113:117\u2013122","journal-title":"J Endocrinol"},{"key":"200_CR7","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJM198405103101904","volume":"310","author":"IN Cholst","year":"1984","unstructured":"Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP (1984) The influence of hypomagnesaemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med 310:1221\u20131225","journal-title":"N Engl J Med"},{"key":"200_CR8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1152\/ajprenal.00312.2003","volume":"286","author":"M Konrad","year":"2004","unstructured":"Konrad M, Schlingmann KP, Gudermann T (2004) Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 286:599\u2013605","journal-title":"Am J Physiol Renal Physiol"},{"key":"200_CR9","first-page":"243","volume":"6","author":"MW Saif","year":"2008","unstructured":"Saif MW (2008) Management of Hypomagnesemia in cancer patients receiving chemotherapy. J Support Oncol 6:243\u2013248","journal-title":"J Support Oncol"},{"key":"200_CR10","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1681\/ASN.V1071616","volume":"10","author":"ZS Agus","year":"1999","unstructured":"Agus ZS (1999) Hypomagnesemia. J Am Soc Nephrol 10:1616\u20131622","journal-title":"J Am Soc Nephrol"},{"key":"200_CR11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/dji242","volume":"97","author":"D Schrag","year":"2005","unstructured":"Schrag D, Chung KY, Flombaum C, Saltz L (2005) Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97:1221\u20131224","journal-title":"J Natl Cancer Inst"},{"key":"200_CR12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3816\/CCC.2006.n.033","volume":"6","author":"MG Fakih","year":"2006","unstructured":"Fakih MG, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6:152\u2013156","journal-title":"Clin Colorectal Cancer"},{"key":"200_CR13","unstructured":"Erbitux package insert. March 2006. ImClone Systems Incorporated, New York, NY 10014, USA, and Bristol-Myers Squibb Company, Princeton, NY 08543, USA"},{"key":"200_CR14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","volume":"8","author":"S Tejpar","year":"2007","unstructured":"Tejpar S, Piessevaux H, Claes K et al (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8:387\u2013394","journal-title":"Lancet Oncol"},{"key":"200_CR15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-009-1090-x","volume":"65","author":"L Liu","year":"2009","unstructured":"Liu L, Cao Y, Tan A, Liao C, Gao F (2009) Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 65:849\u2013861","journal-title":"Cancer Chemother Pharmacol"},{"key":"200_CR16","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"200_CR17","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after Fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311\u20132319","journal-title":"J Clin Oncol"},{"key":"200_CR18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/annonc\/mdm607","volume":"19","author":"J Tol","year":"2008","unstructured":"Tol J, Koopman M, Rodenburg CJ et al (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19:734\u2013738","journal-title":"Ann Oncol"},{"issue":"36","key":"200_CR19","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1200\/JCO.2007.13.0856","volume":"25","author":"CA Butts","year":"2007","unstructured":"Butts CA, Bodkin D, Middleman EL et al (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25(36):5777\u20135784, Erratum in: J Clin Oncol (2008) 26:3295","journal-title":"J Clin Oncol"},{"issue":"34","key":"200_CR20","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23(34):8646\u20138654, Erratum in: J Clin Oncol (2006) 24:724","journal-title":"J Clin Oncol"},{"key":"200_CR21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127","journal-title":"N Engl J Med"},{"key":"200_CR22","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1158\/1078-0432.CCR-08-0077","volume":"14","author":"B Vincenzi","year":"2008","unstructured":"Vincenzi B, Santini D, Galluzzo S et al (2008) Patients treated with cetuximab plus irinotecan as early magnesium reduction in advanced colorectal predictive factor of efficacy and outcome. Clin Cancer Res 14:4219\u20134224","journal-title":"Clin Cancer Res"},{"key":"200_CR23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdq550","volume":"22","author":"B Vincenzi","year":"2011","unstructured":"Vincenzi B, Galluzzo S, Santini D et al (2011) Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 22:1141\u20131146. doi: 10.1093\/annonc\/mdq550","journal-title":"Ann Oncol"},{"key":"200_CR24","doi-asserted-by":"crossref","unstructured":"Vickers MM, Karapetis CS, Tu D et al (2011) The influence of hypomagnesemia (hMg) on overall survival (OS) in phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG\/AGITG CO. 17. J Clin Oncology 29(suppl):abstr. 3601","DOI":"10.1200\/jco.2011.29.15_suppl.3601"},{"key":"200_CR25","unstructured":"Fakih MG (2008) Management of Anti-EGFR\u2013Targeting Monoclonal Antibody\u2013Induced Hypomagnesemia. Oncology. Vol. 22 No. 1. http:\/\/www.cancernetwork.com\/display\/article\/10165\/1147011 1"},{"key":"200_CR26","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Cutsem Van","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664","journal-title":"J Clin Oncol"},{"key":"200_CR27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","volume":"27","author":"JR Hecht","year":"2008","unstructured":"Hecht JR, Mitchell E, Chidiac T et al (2008) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672\u2013680","journal-title":"J Clin Oncol"},{"key":"200_CR28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2009111153","volume":"21","author":"H Dimke","year":"2010","unstructured":"Dimke H, van der Wijst J, Alexander TR et al (2010) Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol 21:1309\u20131316","journal-title":"J Am Soc Nephrol"},{"key":"200_CR29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1681\/ASN.2004070523","volume":"16","author":"JG Hoenderop","year":"2005","unstructured":"Hoenderop JG, Bindels RJ (2005) Epithelial Ca2+ and Mg2+ channels in health and disease. J Am Soc Nephrol 16:15\u201326","journal-title":"J Am Soc Nephrol"},{"key":"200_CR30","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/ki.1997.443","volume":"52","author":"GA Quamme","year":"1997","unstructured":"Quamme GA (1997) Renal magnesium handling: new insights in understanding old problems. Kidney Int 52:1180\u20131195","journal-title":"Kidney Int"},{"key":"200_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1074\/jbc.M311201200","volume":"279","author":"T Voets","year":"2004","unstructured":"Voets T, Nilius B, Hoefs S et al (2004) TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 279:19\u201325","journal-title":"J Biol Chem"},{"issue":"5424","key":"200_CR32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.285.5424.103","volume":"285","author":"DB Simon","year":"1999","unstructured":"Simon DB, Lu Y, Choate KA et al (1999) Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285(5424):103\u2013106","journal-title":"Science"},{"key":"200_CR33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng889","volume":"31","author":"KP Schlingmann","year":"2002","unstructured":"Schlingmann KP, Weber S, Peters M et al (2002) Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 31:166\u2013170","journal-title":"Nat Genet"},{"key":"200_CR34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng901","volume":"31","author":"RY Walder","year":"2002","unstructured":"Walder RY, Landau D, Meyer P et al (2002) Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 31:171\u2013174","journal-title":"Nat Genet"},{"key":"200_CR35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/hmg\/ddl020","volume":"15","author":"D M\u00fcller","year":"2006","unstructured":"M\u00fcller D, Kausalya PJ, Meij IC, Hunziker W (2006) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: blocking endocytosis restores surface expression of a novel claudin-16 mutant that lacks the entire C-terminal cytosolic tail. Hum Mol Genet 15:1049\u20131058","journal-title":"Hum Mol Genet"},{"key":"200_CR36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1086\/508617","volume":"79","author":"M Konrad","year":"2006","unstructured":"Konrad M, Schaller A, Seelow D et al (2006) Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79:949\u2013957","journal-title":"Am J Hum Genet"},{"key":"200_CR37","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1172\/JCI31680","volume":"117","author":"WM Groenestege","year":"2007","unstructured":"Groenestege WM, Th\u00e9bault S, van der Wijst J et al (2007) Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 117:2260\u20132267","journal-title":"J Clin Invest"},{"key":"200_CR38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/34.9.2426343","volume":"34","author":"EC Salido","year":"1986","unstructured":"Salido EC, Barajas L, Lechago J, Laborde NP, Fisher DA (1986) Immunocytochemical localization of epidermal growth factor in mouse kidney. J Histochem Cytochem 34:1155\u20131160","journal-title":"J Histochem Cytochem"},{"key":"200_CR39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/ki.1996.94","volume":"49","author":"L Gesualdo","year":"1996","unstructured":"Gesualdo L, Di Paolo S, Calabr\u00f3 A et al (1996) Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int 49:656\u2013665","journal-title":"Kidney Int"},{"key":"200_CR40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/313228a0","volume":"313","author":"LB Rall","year":"1985","unstructured":"Rall LB, Scott J, Bell GI et al (1985) Mouse prepro-epidermal growth factor synthesis by the kidney and other tissues. Nature 313:228\u2013231","journal-title":"Nature"},{"key":"200_CR41","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1093\/nar\/14.21.8427","volume":"14","author":"GI Bell","year":"1986","unstructured":"Bell GI, Fong NM, Stempien MM et al (1986) Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucl Acids Res 14:8427\u20138446","journal-title":"Nucl Acids Res"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-011-0200-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-011-0200-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-011-0200-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T01:10:33Z","timestamp":1639789833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-011-0200-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,24]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1007\/s11523-011-0200-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,24]]}}}